TP53 status and impact on AML prognosis within the ELN 2022 risk classification

S Fleming; XCH Tsai; R Morris; HA Hou; AH Wei

Journal article

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

S Fleming, XCH Tsai, R Morris, HA Hou, AH Wei

Blood | Published : 2023

DOI: 10.1182/blood.2023020855

Download PDF

Abstract

This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of −7, −5/del(5q), −17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.

University of Melbourne Researchers

Rhiannon Morris Author

Andrew Wei Author

Related Projects (1)

INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive therapy in AML): a multi-arm, precision-based, recursive, platform trial

Grants

Awarded by Ministry of Health and Welfare

Funding Acknowledgements

This study was supported by fellowships and grants from the Australian National Health and Medical Research Council 2011139, 2006403, and 2018071; Medical Research Future Fund 2023403 and 1169950; Metcalf Family Foundation; Ministry of Science and Technology (Taiwan) (MOST 111-2314-B-002-279) ; and Ministry of Health and Welfare (Taiwan) (111-TDU-B-221-114001) .